What is the current status of immune cell therapy for cancer? How does it compare with radiotherapy and chemotherapy?

Immunotherapy for tumors has three unique advantages:

1. Some patients with remarkable efficacy achieve long-term tumor-free or tumor-bearing survival, and this phenomenon is particularly prominent among immune checkpoint inhibitors (PD-1 Ab, CTLA-4 Ab), as can be seen from the survival curves depicted in the data from the clinical trials, unlike chemotherapy, where the survival rate continues to decline over time until 0, the survival rate of immunotherapy continues to benefit this group of patients over time after 5 years (when it drops to about 20%), with long-term benefits. Unlike chemotherapy, where survival rates continue to decline over time until they reach 0, the survival rate for immunotherapy continues to benefit this group of patients over time after 5 years (when it drops to about 20%), and the survival rate becomes almost a stable straight line that does not decrease.

2, immunotherapy for most patients both near-term and long-term toxicities are less than radiotherapy (CAR-T early application of CRS often occurs, but the third generation of CAR-T technology, as well as supportive therapies and related theories of the increasingly sophisticated, this phenomenon has been effectively controlled).

3. Immunotherapy does not exclude traditional therapies such as surgery, radiotherapy, chemotherapy, etc. On the contrary, a reasonable combination of immunotherapy and traditional anti-tumor therapies can often have a positive effect.